UroGen Pharma Ltd.'s SEC filings document operating results, product revenue disclosures, financing agreements and governance matters for a biotechnology company focused on urothelial and specialty cancers. Recent 8-K reports furnish quarterly and annual financial results tied to JELMYTO and ZUSDURI, commercial launch updates, research and development expenses, reimbursement matters and pipeline disclosures involving UGN-103 and UGN-501.
Other filings describe material definitive agreements, including term-loan refinancing and credit arrangements with BioPharma Credit entities, as well as capital-structure information for ordinary shares listed on Nasdaq. Definitive proxy statements cover board matters, executive compensation, equity awards, pay-versus-performance tables and shareholder voting matters.
Holden Stuart, a director of UroGen Pharma Ltd. (URGN), received equity awards on 08/26/2025. The Form 4 reports a stock option for 10,000 ordinary shares with a stated price of $19.50 and 8,000 restricted stock units (RSUs), both granted on 08/26/2025. The Form shows 10,000 stock options and 8,000 RSUs beneficially owned following the reported transactions, each held in a direct ownership form. The disclosures state both the option and RSU awards vest in equal quarterly installments over one year, subject to Continuous Service under the 2017 Equity Incentive Plan. The Form 4 is signed by an attorney-in-fact on 08/27/2025.
Cynthia M. Butitta, a director of UroGen Pharma Ltd. (URGN), reported equity awards granted on 08/26/2025. She was granted a stock option to buy 10,000 ordinary shares with an exercise price of $19.50 and a 10-year term expiring 08/26/2035, and 8,000 restricted stock units (RSUs) each convertible into one ordinary share. Both the option and the RSUs were acquired on 08/26/2025 and are held directly.
The option and RSUs vest in equal quarterly installments over one year, conditioned on the director's continued service under the companys 2017 Equity Incentive Plan. The form was signed by an attorney-in-fact on 08/27/2025. The reporting persons address is listed in Princeton, NJ.
UroGen Pharma Ltd. (URGN) director Wen Leana was granted equity awards on 08/26/2025: a stock option for 10,000 ordinary shares with a $19.50 exercise price and 8,000 restricted stock units (RSUs). The option and RSUs vest in equal quarterly installments over one year, subject to the director's continued service under the companys 2017 Equity Incentive Plan. After the grants, the reporting person beneficially owns 10,000 shares underlying the option and 8,000 shares underlying the RSUs, each shown as direct ownership. The Form 4 was signed by an attorney-in-fact on 08/27/2025.
Arie Belldegrun, a director of UroGen Pharma Ltd. (URGN), reported an equity award on 08/26/2025. The Form 4 shows acquisition of 20,000 stock options with an exercise price of $19.50. The options become exercisable on 08/26/2025 and expire on 08/26/2035, and the reporting person beneficially owns 20,000 underlying ordinary shares following the transaction. Per the filing, the shares underlying the option will vest in equal quarterly installments over one year, contingent on the directors continuous service under the 2017 Equity Incentive Plan. The Form 4 was signed via attorney-in-fact on 08/27/2025.
UroGen Pharma Ltd. reported the results of its 2025 annual shareholder meeting. Shareholders approved an Amended and Restated Non-Employee Director and Officer Compensation Policy and an amendment to the 2017 Equity Incentive Plan that, among other changes, increases the number of ordinary shares authorized for issuance under the plan by 2,750,000 shares.
All seven director nominees were elected. Shareholders gave advisory approval to the compensation of named executive officers and chose an annual schedule for future advisory votes on executive pay, which the board adopted until at least the 2031 annual meeting. Shareholders also approved the engagement of PricewaterhouseCoopers LLP as independent auditor until the 2026 annual meeting.
RA Capital Management, L.P., two individuals (Peter Kolchinsky and Rajeev Shah) and RA Capital Healthcare Fund, L.P. filed an Amendment to Schedule 13G for UroGen Pharma Ltd. (ticker URGN) reporting ordinary shares, CUSIP M96088105. The filing states that as of June 30, 2025 each Reporting Person beneficially owned 0 shares (0.0%) of UroGen and disclaims status as a group. The filing provides the Reporting Persons' principal business address in Boston and certifies the holdings were not acquired to influence control of the issuer.
Mark Schoenberg, Chief Medical Officer of UroGen Pharma Ltd. (URGN), sold 10,000 ordinary shares on 08/11/2025 at a weighted-average price of $17.69 per share. After the transaction he directly beneficially owned 148,229 shares. The filing reports the sale under Transaction Code S and notes the shares were sold in multiple trades at prices ranging from $17.63 to $17.76.
No derivative (options, warrants, or convertible) transactions are reported on this Form 4 and the reporting person indicates availability of further breakdown information on request.
Paradigm BioCapital and affiliated reporting persons disclosed passive beneficial ownership of UroGen Pharma Ltd. ordinary shares. The Adviser, the Adviser GP and Senai Asefaw each report sole beneficial ownership of 2,332,066 shares, equal to 5.0% of the outstanding class, while Paradigm BioCapital International Fund Ltd. reports 2,056,187 shares or 4.4%. These percentages are calculated using 46,264,132 ordinary shares outstanding as reported by the issuer.
The statement is filed on Schedule 13G, which the reporting persons use to indicate passive holdings; the filing includes a certification that the shares were not acquired to change or influence control and disclaims beneficial ownership beyond the shares directly held. Principal business addresses and organizational jurisdictions for each reporting person are provided.